LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
Ballerup, Denmark, and Seoul, Korea, August 27th, 2019: LEO Pharma, a global leader in medical dermatology, and Korean JW Pharmaceutical today announced that LEO Pharma has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a pharmacokinetics study in the US.
The filing is based on the two companies’ ongoing collaboration on the development of JW1601/LP0190, an oral treatment for atopic dermatitis for which JW Pharmaceutical out-licensed their investigatory drug to LEO Pharma in August 2018. JW Pharmaceutical has since January this year conducted phase 1 clinical trial consisting of a single dose and repeated dose studies in healthy adults. Recently the single dose phase for Koreans was successfully completed with acceptable safety and tolerability observed up to the highest dose, 5th cohort. Based on this trial LEO Pharma has now filed a protocol for a pharmacokinetics study in US – a small clinical trial with healthy volunteers to further evaluate the pharmacokinetics of JW016/LP0190.
“We are excited to see the progress of our collaboration with JW Pharmaceuticals that is now enabling us to file the IND application to the FDA and take the next step towards making an oral treatment for atopic dermatitis available. The unmet needs in this disease area are huge and an oral treatment will add substantially to the treatment options to the benefit of the many people living with this disease”, says Kim Kjoeller, Executive Vice President, Global Research & Development at LEO Pharma.
S.Y Lee, Senior Executive Vice President, Chief of Corporate Development Division said, “As the single-dose study for Koreans has been completed smoothly, LEO Pharma was able to apply for this study plan in US.” He also added that “JW Pharmaceutical will further strengthen our partnership with LEO Pharma in the future and develop JW1601 as a new drug for treatment of atopic dermatitis that will play a pivotal role in the global market.”
JW1601 is a H4R antagonist expected to have anti-pruritic and anti-inflammatory effect in atopic dermatitis. The new drug candidate is developed as an oral treatment, a more convenient route of administration with the potential to improve the compliance for the patient.
Contacts
Contact:
LEO Pharma
Henrik Kyndlev
+45 3140 6180
hdtdk@leo-pharma.com
US inquiries
LEO Pharma US
Rhonda Sciarra
+1 973 637 8019
+1 862 337 0675
rasus@leo-pharma.com
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, visit www.leo-pharma.com or follow us on LinkedIn: www.linkedin.com/company/leo-pharma
About JW PHARMACEUTICAL CORPORATION
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945 and is listed on the Korea Exchange Market under the symbol "001060 ".
More information is available at http://www.jw-pharma.co.kr/pharma/en/main.jsp.
ABOUT JW1601
JW1601 is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. JW1601 is currently conducting pre-clinical toxicity study and looking for phase 1 IND submission in 2018 in Korea. JW1601 is an investigational compound that is not approved for any use in any country.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership13.5.2025 13:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 13 May 2025 -- At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future. In light of this, we are announcing the following changes to our Executive Management team: We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025. Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania). Lisa Elliott, currently Vice President, Gl
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis9.5.2025 12:00:00 CEST | Pressemeddelelse
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom